Retatrutide UK — the triple-agonist explained

Retatrutide is a synthetic 39-amino-acid peptide with a fatty-acid side chain that binds serum albumin, extending its half-life to roughly six days and enabling weekly dosing. Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), retatrutide activates a third receptor — the glucagon receptor — which drives hepatic energy expenditure and lipolysis. That is the mechanism the higher weight-loss ceiling sits on.

For a side-by-side breakdown of the pharmacology, see retatrutide vs tirzepatide, and for how it fits inside the wider GLP-1 landscape see the GLP-1 brand names map.

Retatrutide is not authorised by the MHRA. It is not available on NHS prescription, not available on private prescription, and it is not listed in the BNF. UK researchers work with reference-grade lyophilised retatrutide sourced under laboratory-supply channels for in vitro and characterisation use only.

Any UK-facing claims that retatrutide is "available" as a medicine misrepresent its status. The molecule is in Phase 3 (Eli Lilly's TRIUMPH programme) with regulatory submission expected after topline data — earliest plausible MHRA authorisation is post-Phase-3 readout.

The pivotal Phase 2 obesity study (Jastreboff et al., NEJM 2023) enrolled 338 adults with BMI ≥30 (or ≥27 with comorbidity), randomised to placebo or retatrutide (1, 4, 8 or 12 mg weekly). At 48 weeks the 12 mg arm lost a mean 24.2% of body weight versus 2.1% for placebo. No plateau was reached at 48 weeks — the weight-loss curve was still descending.

Phase 2 T2D data (Rosenstock et al., Lancet 2023) showed HbA1c reductions of up to 2.0 percentage points at 12 mg alongside 16.9% weight loss over 36 weeks. Phase 3 (TRIUMPH-1 through TRIUMPH-4) is running now, covering obesity, obesity + T2D, obesity + cardiovascular disease and obesity + knee osteoarthritis.

Trial protocols use slow 16–20 week titration through 2 mg → 4 mg → 8 mg → 12 mg to blunt the gastrointestinal side-effect profile (nausea, decreased appetite, transient diarrhoea). Peak trial arm was 12 mg weekly. Full schedule and per-dose U-100 syringe-unit conversions are in the retatrutide dosage UK guide.

For research reconstitution: lyophilised retatrutide is reconstituted with bacteriostatic water. Convert vial mg + BAC water mL into precise U-100 insulin-syringe units using the reconstitution calculator, and for microgram conversions use the dose conversion calculator. For the full method see the ultimate guide to peptide reconstitution.

Lyophilised retatrutide is stable for months at 2–8 °C in the sealed vial. Once reconstituted with BAC water, expect ~28 days refrigerated stability. Protect from light. Avoid freeze-thaw cycles — they degrade the peptide backbone irreversibly. Full protocol in the storage & stability guide.

A reference-grade retatrutide vial should ship with a batch-specific certificate of analysis showing HPLC purity ≥98%, mass-spec identity confirmation, and residual-solvent data. Anything less is not a research reagent — it is an unspecified powder. See the HPLC & CoA guide for how to read one.

In the UK, researchers in this library reference peptidesuk4u.co.uk, which publishes lot-level HPLC CoAs alongside every listing — the analytical standard the cornerstone guide describes.